Michael Mollerus

Davis Polk is advising Roche on its acquisition of the outstanding shares of Foundation Medicine, Inc. not already owned by Roche at a price of $137.00 per share in cash. The transaction is…

Davis Polk advised the joint book-running managers in connection with the $172 million public offering of common stock of Deciphera Pharmaceuticals, Inc. The common stock is listed on…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Kennametal Inc. of $300 million aggregate principal amount of 4.625% senior notes due 2028. …

Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to which its indirect wholly owned subsidiary, Valeant Pharmaceuticals…

Davis Polk advised the representatives of the several underwriters in connection with Iterum Therapeutics plc’s initial public offering of 6,150,000 ordinary shares, at $13.00 per…

Davis Polk advised the representatives of the underwriters in connection with the SEC-registered offering of 24,640,000 shares of common stock of Melinta Therapeutics, Inc., including…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 4,057,500 shares of common stock of Calyxt, Inc., including 457,500…

Davis Polk is advising IHS Markit on its $1.855 billion acquisition of Ipreo from private equity funds managed by Blackstone and the Goldman Sachs Merchant Banking Division. The acquisition…

Davis Polk advised MSCI Inc. in connection with a Rule 144A/Regulation S offering of $500 million aggregate principal amount of its 5.375% senior notes due 2027 and a concurrent amendment…

Davis Polk advised the joint book-running managers in connection with the offering by Canadian Pacific Railway Company of $500 million aggregate principal amount of 4.000% notes due…